Novo Nordisk's sales growth will be negatively impacted in 2022

The pharmaceutical company's expectations for the consequences of the new Chinese procurement model for insulin have been released, and they are not good news for the firm.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk is predicting that global sales growth will be negatively impacted by 3 percent in 2022, it reports in a press release on Friday.

This is the result of a new a new insulin procurement model in China, the Volume Based Procurement (VBP) tender, which the Chinese National Healthcare Security Administration has implemented, resulting in lower prices and volumes of insulin sold in China.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs